Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vascular Access Patency Clear all
Terminated Not applicable Interventional

Clipped Versus Handsewn Arteriovenous Fistula Anastomosis

NCT01669850
View directory record Official record
Conditions
Arteriovenous Fistula Complications and Failure
Interventions
Clipped anastomosis, Handsewn anastomosis
Device · Procedure
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

NCT02414841
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vonapanitase, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

NCT00322270
View directory record Official record
Conditions
Thrombosis, Venous Thrombosis, Catheter Occlusion
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Casa Grande, Arizona • Soquel, California • Boynton Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

Aggrenox Prevention of Access Stenosis

NCT00067119
View directory record Official record
Conditions
Kidney Failure
Interventions
Aggrenox, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Iowa City, Iowa • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

NCT00179647
View directory record Official record
Conditions
Multiple Myeloma
Interventions
lenalidomide, dexamethasone
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
63
States / cities
Scottsdale, Arizona • Berkeley, California • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Open Access Audio

NCT04452331
View directory record Official record
Conditions
Hypertension, Diabetes
Interventions
Open Access Audio, No Access, Patient and Provider Aware of Recording, No Access, Provider Unaware of Recording
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT00448708
View directory record Official record
Conditions
Kidney Diseases, ESRD
Interventions
Vascular Wrap Paclitaxel-Eluting Mesh, Lifespan® ePTFE Vascular Graft
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

NCT00039767
View directory record Official record
Conditions
Thrombosis
Interventions
Lepirudin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study

NCT00890045
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

Oxidative Stress and Hemodialysis Access Failure

NCT00410449
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jul 22, 2026, 10:22 AM EDT
Approved For Marketing No phase listed Expanded access

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

NCT04552691
View directory record Official record
Conditions
Fabry Disease
Interventions
Pegunigalsidase Alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 22, 2026, 10:22 AM EDT
Suspended Not applicable Interventional

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

NCT04559334
View directory record Official record
Conditions
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Tetrasodium EDTA Catheter Lock Solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Recruiting Phase 4 Interventional

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
17
States / cities
Irvine, California • Orange, California • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Approved For Marketing No phase listed Expanded access

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

NCT02477891
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

NCT02335099
View directory record Official record
Conditions
End Stage Renal Disease, Vascular Access Patency
Interventions
ticagrelor, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study

NCT00669851
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AI-700
Drug
Lead sponsor
Acusphere
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2008 · Synced Jul 22, 2026, 10:22 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

NCT00655252
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
15
States / cities
Springdale, Arkansas • Aurora, Colorado • Ocoee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence

NCT00895479
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Graft placement surgery plus Trinam therapy
Procedure
Lead sponsor
Ark Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Long Beach, California • Paducah, Kentucky • Baton Rouge, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Jul 22, 2026, 10:22 AM EDT